[Management of chemotherapy-induced anemia in lung cancer].

Date publication

octobre 2015

Journal

Revue des maladies respiratoires

Auteurs

Membres identifiés du Cancéropôle Est :
Dr CLEMENT-DUCHENE Christelle , Pr MARTINET Yves

Tous les auteurs :
Tiotiu A, Clément-Duchêne C, Martinet Y

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/26051503

Résumé

The prevalence of chemotherapy-induced anemia in lung cancer is estimated at about 80%.

Mots clés

Anemia, chemically induced, Antineoplastic Agents, adverse effects, Biosimilar Pharmaceuticals, therapeutic use, Blood Transfusion, Clinical Trials as Topic, Combined Modality Therapy, Disease Management, Erythrocyte Transfusion, Fatigue, etiology, Hematinics, administration & dosage, Hemoglobins, analysis, Humans, Iron, therapeutic use, Lung Neoplasms, blood, Practice Guidelines as Topic, Quality of Life, Radiotherapy, adverse effects, Recombinant Proteins, therapeutic use

Référence

Rev Mal Respir. 2015 Oct;32(8):809-21